GDTC — CYTOMED THERAPEUTICS LIMITED ORDINARY SHARES (Healthcare >> Biotechnology)
GDTC FAQ
What is GDTC's ROE?
CYTOMED THERAPEUTICS LIMITED ORDINARY SHARES reports a Return on Equity (ROE) of -59.85%.
What is GDTC's dividend yield?
CYTOMED THERAPEUTICS LIMITED ORDINARY SHARES offers a dividend yield of 0.00%.
What is GDTC's Deepscope Quality Score?
Deepscope rates GDTC's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy GDTC?
Deepscope's AI Timing Score for GDTC is 6 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does GDTC belong to?
CYTOMED THERAPEUTICS LIMITED ORDINARY SHARES is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 1.29
Price
0.11
(9.32%)
Day Change
|
|
|---|
GDTC Chất lượng tổng thể của cố phiếu Không tốt ( Chất lượng = 23) và Thời điểm mua ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
Tỷ lệ ROE tương đối thấp
Tỷ lệ ROA tương đối thấp
[-] Tốc độ tăng trưởng ROE dưới mức tiêu chí của chúng tôi.
Lịch sử ROE tương đối thấp
ROE đang giảm đáng kể
ROA quá thấp so với ROE
Tốc độ tăng trưởng ROA dưới mức tiêu chí của chúng tôi.
Tăng trưởng ROA hiện tại đang dưới mức tiêu chí của chúng tôi.
Biên lợi nhuận ròng tương đối thấp.
Lịch sử Biên lợi nhuận ròng tương đối thấp.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
Chi tiết hơn, sẽ thấy rằng các yếu tố chất lượng Không tốt , Sức khỏe tài chính Không tốt , và khả năng kiếm lợi nhuận Không tốt lắm , ...
| Yếu tố Chất lượng |
|
42% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 96 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 1.29 |
| PBV / Sector |
2.22 / 4.63
|
| Earning Per Share | -0.34 |
| PE / Sector |
N/A / 17.43
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
0.03 M
GREAT
|
| Average 1W Daily Value |
5563.008200000000
|
| Yếu tố Kỹ thuật |
|
71% |
| Sức khỏe tài chính |
|
45% |
| Khả năng kiếm lợi nhuận |
|
52% |
| Lợi tức cho nhà đầu tư |
|
4% |
| Chi tiết đăng ký |
| Analyze Date | 2026-06-06 09:09:25 |
| Symbol | GDTC |
| Name | CYTOMED THERAPEUTICS LIMITED ORDINARY SHARES |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 11.83 M |
| Par Value | N/A |
| Calculated From | YearEnd |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 15.21 / 8,857.28 |
| Tin tức, Dự báo ước tính |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 1 Commonwealth Lane, Singapore, Singapore, 149544
Phone: 65 6250 7738
Website: https://w2.cytomed.sg
Sector: Healthcare >> Biotechnology
Description: CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company's lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord-derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore; and Business and Research Collaboration Agreement with SunAct Cancer Institute Private Limited to conduct clinical trials for the GMP grade CTM-GDT. CytoMed Therapeutics Limited was incorporated in 2018 and is headquartered in Singapore.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Google